Associate editor: P.C. MolenaarCardiac cachexia: A systematic overview
Introduction
The treatment of chronic heart failure (CHF) has made significant advances over the last two decades. This applies likewise for the establishment of the diagnosis of this syndrome using different single and multi-biomarker approaches (Cowie et al., 1997, Kempf et al., 2007, von Haehling et al., 2007b). Even more so, our understanding of the disease has developed from the rather simplistic model of mere pump failure to that of a complex disease that affects multiple body systems. Despite this, the clinical perspective remains poor, because about half of the patients with CHF die within 4 years of diagnosis (Remme & Swedberg, 2001). This truly devastating prognosis is comparable to that of some types of cancer (Stewart et al., 2001). Overall, the incidence of CHF is steadily increasing in most European countries and in the United States. Current estimates amount to an incidence of 0.1–0.5% per year, and the numbers are doubling with each decade to reach 3% in those over the age of 75. The prevalence of CHF has been estimated at around 0.3–2.4%, which implies that 5 million people in the United States are affected (American Heart Association, 2005). Heart failure accounts for 970,000 hospitalizations and 12–15 million outpatient office visits in this country per year. This causes health-care associated costs of 28 billion US-dollar.
The situation worsens considerably once cardiac cachexia has been diagnosed. Although the definition of this clinical entity has been subject to debate over years (see below), all researchers have unanimously agreed on the poor prognosis of the cachectic patient. In unselected patients with CHF, mortality rates were as high as 50% in the cachectic subset compared to 17% in the non-cachectic subset at 18 months of follow-up (Anker et al., 1997, Anker et al., 1997, Anker et al., 1997). Cachexia is not a unique feature of CHF, but is also seen in terminal stages of other chronic illnesses, including cancer, sepsis, rheumatoid arthritis, and acquired immunodeficiency syndrome (AIDS).
Cachexia is not only associated with poor outcomes, but also with an unfavourable response to drug treatment and poor quality of life. It has been observed in patients with cancer that survival is impaired already at a weight loss of 5% (Dewys et al., 1980). Weight loss exceeding 30% is incompatible with life (Fearon et al., 1992). It is among the most common misconceptions that one of the underlying causes of cachexia is anorexia, i.e. loss of appetite. Although anorexia is certainly a common feature of the diseases leading to the development of cachexia, this feature alone cannot explain the metabolic changes observed during this perturbation. Importantly, nutritional supplementation cannot reverse the process of losing weight in patients with genuine cachexia, which is possible in patients who suffer from starvation or anorexia. Still, nutritional aspects have to be considered when treating patients with cachexia.
Weight loss in the cachectic patient predominantly affects muscle protein, however, bone and fat tissue are likewise affected later in the course of the disease. The factors that trigger the progression from clinically and body weight stable, ambulatory CHF to cardiac cachexia remain poorly understood. The timelines differ widely between patients. The aim of this review is to provide a broad overview of the current knowledge of cardiac cachexia. This includes the ongoing discussion about how to define cachexia, intracellular and extracellular signalling, and potential therapeutic approaches.
Section snippets
Definition of cardiac cachexia
Body weight is a dynamic parameter, and it has a certain rhythm over the lifespan (Wallace & Schwartz, 2002). Currently, public opinion is more concerned with weight gain than weight loss, and therefore most of the programs in adults are aiming at the reduction of body size (Dansinger et al., 2007). However, weight loss due to body wasting may reflect serious disease and has to be considered with particular attention. Cachexia (Greek: kakós – bad; hexis – condition) constitutes its terminal
Immune activation
One key aspect of CHF and cardiac cachexia like many other forms of cachexia is inflammatory immune activation. This has been first described by Levine and associates in 1990 (Levine et al., 1990). Indeed, it may well be that activation of the pro-inflammatory mediator tumour necrosis factor-α (TNFα) is the final common pathway that links all forms of cachexia. Since the initial description of TNFα activation in CHF, at least five different hypotheses have been suggested to explain the origin
Brief summary
In this section, both positive and negative key modulators of appetite will be reviewed. Feeding is a key component of a satiety-hunger homeostatic model (Fig. 1). Although a simple but vital daily process, it is influenced by many pathways and/or mechanisms, which are still not completely understood (Table 2) (Brunetti et al., 2005). However, the hypothalamus has been identified as the central regulating site of appetite (Fig. 2). Two areas can be differentiated: a lateral “feeding area“ and a
Brief summary
This section gives an overview of the wasting process seen in cardiac cachexia, which does not only involve lean tissue, i.e. skeletal muscle, but also fat tissue and bone. Skeletal muscle is lost due to an imbalance of protein synthesis and proteolysis. Typically pro-inflammatory cytokines induce proteolytic systems, while simultaneously reducing the anabolic IGF-1 signaling. Lean body mass depletion is one of the major characteristics of cachexia. Indeed, up to 68% of patients with CHF have
Brief summary
There are currently no approved therapies to treat of weight loss as such in cardiac cachexia. This section aims to give an overview of the different treatment strategies that might be pursued in preventing or treating loss of tissue. Some of these have been shown to provide benefit, as data from retrospective analyses show, some have even shown their efficacy in clinical studies. Others, however, may prove less effective although they have therapeutic appeal from a theoretical point of view.
Conclusion
The pathophysiology of cardiac cachexia is exceedingly complex, and we still do not understand when and how CHF progresses into this syndrome. Pro-inflammatory cytokines and especially TNFα certainly play an important part. However, therapies that targeted specific single cytokines have largely failed, and it appears that broader approaches are required. One potential therapeutic aim is the inhibition of intracellular signalling pathways like NF-κB, which is also likely to inhibit
References (361)
- et al.
Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure
J Card Fail
(2002) - et al.
Loss of bone mineral in patients with cachexia due to chronic heart failure
Am J Cardiol
(1999) - et al.
How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH
Int J Cardiol
(2002) - et al.
Elevated soluble CD14 receptors and altered cytokines in chronic heart failure
Am J Cardiol
(1997) - et al.
Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study
Lancet
(2003) - et al.
Wasting as independent risk factor for mortality in chronic heart failure
Lancet
(1997) - et al.
Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone
J Am Coll Cardiol
(2001) - et al.
Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS
J Pain Symptom Manage
(1995) - et al.
Ghrelin can bind to a species of high density lipoprotein associated with paraoxonase
J Biol Chem
(2003) - et al.
A role for beta-melanocyte-stimulating hormone in human body-weight regulation
Cell Metabolism
(2006)
IKKbeta/NF-kappaB activation causes severe muscle wasting in mice
Cell
Prevalence and haemodynamic correlates of malnutrition in severe congestive heart failure secondary to ischaemic or idiopathic dilated cardiomiopathy
Am J Cardiol
Muscle and serum changes with salbutamol administration in aerobically exercised rats
Comp Biochem Physiol C Toxicol Pharmacol
Therapeutic effects of ghrelin on endotoxic shock in rats
Eur J Pharmacol
Growth hormone resistance in chronic heart failure and its therapeutic implications
J Card Fail
Anticytokine treatment prevents the increase in the activity of ATP-ubiquitin- and Ca(2+)-dependent proteolytic systems in the muscle of tumour-bearing rats
Cytokine
Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care
Lancet
The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis
Neuron
Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex. transfer from CD14 to TLR4 and MD-2
J Biol Chem
A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure
J Am Coll Cardiol
Prognostic effect of weight loss prior to chemotherapy in cancer patients
Am J Med
The significance of leptin in humans – do we know it yet?
Int J Cardiol
Cardiac cachexia in early literature: a review of research prior to Medline
Int J Cardiol
Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNF-alpha
Int J Cardiol
Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure
J Am Coll Cardiol
The discovery and development of HMG-CoA reductase inhibitors
J Lipid Res
Cachexia: a new definition
Clin Nutr
Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis
Am J Clin Nutr
The cardiac component of cardiac cachexia
Am Heart J
Wasting of the left ventricle in patients with cardiac cachexia: a cardiovascular magnetic resonance study
Int J Cardiol
Time course of complete normalization of left ventricular hypertrophy during long-term antihypertensive therapy with angiotensin converting enzyme inhibitors
Am J Hypertens
A brief history of testosterone
J Urol
Pathophysiologic quantities of endotoxin-induced tumor necrosis factor-alpha release in whole blood from patients with chronic heart failure
Am J Cardiol
Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent
Proc Natl Acad Sci USA
Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study
JAMA
Heart Disease and Stroke Statistics
Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia
Circulation
Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure
Eur Heart J
Does carvedilol prevent and reverse cardiac cachexia in patients with severe heart failure? Results of the COPERNICUS study
Eur Heart J
Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging
Circulation
Prevention and reversal of cachexia in patients with chronic heart failure by bisoprolol: results from the CIBIS II-study
J Am Coll Cardiol
Cardiac cachexia
Ann Med
Inflammatory mediators in chronic heart failure: an overview
Heart
Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone
J Clin Endocrinol Metab
Nutrition and cardiac cachexia
Curr Opin Nutr Metab Care
Pentoxifylline in ischemic, hypertensive and idiopathic-dilated cardiomyopathy: effects on left-ventricular function, inflammatory cytokines and symptoms
Eur J Heart Fail
The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway
J Clin Invest
Thalidomide and immunomodulatory drugs in the treatment of cancer
Expert Opin Investig Drugs
Oxygen free radicals and congestive heart failure
Br Heart J
Tumour necrosis factor in chronic heart failure: a peripheral view on pathogenesis, clinical manifestations and therapeutic implications
Drugs
Cited by (299)
Predictive value of cholinesterase in patients with heart failure: A new blood biochemical marker of undernutrition
2023, Nutrition, Metabolism and Cardiovascular DiseasesClinical implications of remote dielectric sensing system to estimate lung fluid levels
2023, Journal of CardiologyPrognostic relevance of gradual weight changes on long-term mortality in chronic heart failure
2023, Nutrition, Metabolism and Cardiovascular DiseasesCachexia Is Associated With Adverse Outcomes in Patients Admitted With Heart Failure
2023, American Journal of CardiologyThe complex pathophysiology of cardiac cachexia: A review of current pathophysiology and implications for clinical practice
2023, American Journal of the Medical SciencesImpact of Preoperative Liver Function on Short-Term HeartMate 3 Outcomes
2022, American Journal of Cardiology